Embecta
EMBC
About: Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.
Employees: 2,100
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
0.23% less ownership
Funds ownership: 98.31% [Q1] → 98.08% (-0.23%) [Q2]
8% less first-time investments, than exits
New positions opened: 48 | Existing positions closed: 52
3% less funds holding
Funds holding: 365 [Q1] → 355 (-10) [Q2]
21% less repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 107
24% less capital invested
Capital invested by funds: $728M [Q1] → $557M (-$171M) [Q2]
50% less call options, than puts
Call options by funds: $412K | Put options by funds: $828K
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
|
BTIG
Marie Thibault
|
$25
|
Buy
Reiterated
|
5 Sep 2025 |
|
Mizuho
Anthony Petrone
|
$12
|
Neutral
Maintained
|
16 Jul 2025 |
Financial journalist opinion
Based on 7 articles about EMBC published over the past 30 days
